Neutralizing antibody response and SARS severity.
Emerg Infect Dis
; 11(11): 1730-7, 2005 Nov.
Article
in En
| MEDLINE
| ID: mdl-16318725
ABSTRACT
Using the Taiwan nationwide laboratory-confirmed severe acute respiratory syndrome (SARS) database, we analyzed neutralizing antibody in relation to clinical outcomes. With a linear mixed model, neutralizing antibody titer was shown to peak between week 5 and week 8 after onset and to decline thereafter, with a half-life of 6.4 weeks. Patients with a longer illness showed a lower neutralizing antibody response than patients with a shorter illness duration (p = 0.008). When early responders were compared with most patients, who seroconverted on and after week 3 of illness, the small proportion (17.4%) of early responders (antibody detectable within 2 weeks) had a higher death rate (29.6% vs. 7.8%) (Fisher exact test, p = 0.004), had a shorter survival time of <2 weeks (Fisher exact test, p = 0.013), and were more likely to be > 60 years of age (Fisher exact test, p = 0.01). Our findings have implications for understanding the pathogenesis of SARS and for SARS vaccine research and development.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Severe Acute Respiratory Syndrome
/
Severe acute respiratory syndrome-related coronavirus
/
Antibodies, Viral
Type of study:
Prognostic_studies
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Emerg Infect Dis
Journal subject:
DOENCAS TRANSMISSIVEIS
Year:
2005
Document type:
Article
Affiliation country:
Taiwán